ONO Pharma says Taiwan approves Opdivo perioperative regimen for resectable NSCLC

• ONO Pharmaceutical’s Taiwan unit secured TFDA clearance on Aug. 19 for OPDIVO in resectable non-small cell lung cancer.
• Label covers perioperative use: neoadjuvant OPDIVO with platinum-doublet chemotherapy, then surgery, then adjuvant OPDIVO monotherapy.
• Decision based on CheckMate-77T results showing improved event-free survival, with higher pathologic complete response and major pathologic response.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ONO Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.